Avista supporting cGMP manufacture of hapten for opioid vaccine development

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/Remains)
(Image: iStock/Remains)

Related tags: Vaccine, Contract

Avista Pharma Solutions, Inc. has been contracted to manufacture an opioid-derived small molecule, which is a component of a conjugate vaccine being developed to treat opioid addiction.

The vaccine is being developed by the Minneapolis Medical Research Foundation (MMRF), a non-profit subsidiary of the Hennepin Healthcare System, Inc. in Minneapolis, MN.

The research is funded by a three-year grant to the MMRF from the National Institute on Drug Abuse and will “help with the unbiased epidemic that is causing great damage to the people of this country and around the world​,” Tim Compton, Avista’s vice president of business development told Outsourcing-Pharma.com.

Under the services agreement, Avista Pharma Solutions​ will support the development and manufacturing of the small molecule (hapten​) associated with the vaccine.

The contract development and manufacturing organization (CDMO) will produce a cGMP batch of the molecule to support manufacturing of the vaccine and finished dosage form for the first-in-human studies.

Currently we are engaged through the first phase in human production of the hapten, but hope to continue supporting and working with MMRF as future development milestones are achieved​,” explained Compton.

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Related suppliers

Follow us


View more